Treatment Trial for Psychogenic Nonepileptic Seizures


I'm Interested

Trial ID: NCT00835627


The investigators propose that patients who receive targeted pharmacotherapy (sertraline) or focused psychotherapy (cognitive behavioral therapy-informed psychotherapy (CBT-ip) for NES) or combined treatment (CBT-ip + sertraline) will report fewer nonepileptic seizures (NES) compared to patients who receive community care / treatment as usual (TAU). The purpose of this study is to provide pilot testing and data to inform the future multicenter randomized controlled trial based on the hypothesis.

Official Title

Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures

Stanford Investigator(s)

Charles DeBattista
Charles DeBattista

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult)


Inclusion Criteria:

   - Video electroencephalogram (EEG) confirmed diagnosis of NES

   - Have at least one nonepileptic seizure per month

   - Able to complete self report symptom scales

   - Not receiving optimized sertraline

Exclusion Criteria:

   - Equivocal EEG findings

   - using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan

   - allergy/sensitivity to sertraline

   - current alcohol/drug dependence

   - serious medical illness requiring current hospitalization


other: Standard Care

drug: Sertraline

behavioral: CBT-ip

other: Combined (sertraline + CBT-ip)


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jessica Hawkins